Circassia Initiates Further Phase II Clinical Study Of Toleromune(R) Anti Allergy Technology
Oct 3rd 2008Drug InformationAllergies
Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
